CompanyKPHMW KPRXNasdaq, OTCEncinitas, CA

Kiora Pharmaceuticals Inc

Kiora Pharmaceuticals develops small-molecule therapies for retinal disease.

SEC EDGAR ClinicalTrials.gov kiorapharma.com

SCHEDULE 13GSep 17Latest SEC filing

Sep 8Latest story

September 2026

Kiora Pharmaceuticals names Keith Lane as EVP of Clinical Development and Regulatory Affairs

Sep 8PeopleKiora Pharmaceuticals Inc

August 2026

Kiora licenses South Korean rights to KIO-301 to Chong Kun Dang

Aug 19PartnershipKiora Pharmaceuticals Inc

Kiora reports Q2 2026 results, advances KIO-301 and KIO-104 trials

Aug 7Quarterly updateKIO-104 Kiora Pharmaceuticals Inc